Cephalon/Alkermes Vivitrex User Fee Date Extended
FDA has extended the user fee date for Cephalon's and Alkermes' alcohol dependency therapy Vivitrex (naltrexone) by three months to Dec. 30, the companies announced Sept. 20
FDA has extended the user fee date for Cephalon's and Alkermes' alcohol dependency therapy Vivitrex (naltrexone) by three months to Dec. 30, the companies announced Sept. 20